Latest Breaking News On - Novartis external communications - Page 3 : comparemela.com

Novartis provides update on Phase III CANOPY-A study

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small.

United statesIsabella zinckJeff legosVeronique boissonnasNicole zinsli sommBiochim biophys actaSamir shahJulie masowParag mahantiSloan simpsonAlina levchukGlobal oncology communicationsAmerican joint committee on cancerWorld health organizationNovartis us external communicationsNovartis external communications

New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy

First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal. | June 30, 2022

United statesIsabella zinckSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNicole zinsli sommDrug administrationNovartis us external communicationsNovartis external communicationsExchange commissionEuropean medicines agencyAmerican cancer societyToday novartisNorth america

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomIsabella zinckArzum ustunNicole zinsli sommSamir shahParag mahantiJulie masowNeil hendersonSloan simpsonPaul barasaAlina levchukNovartis institute for tropical diseasesNovartis institutes for biomedical researchWorld health organization

Novartis Pharma AG: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least

United statesEast hanoverIsabella zinckHaseeb ahmadAmy wolfNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowSloan simpsonAndreas hochhausAlina levchukOncology at jena university hospitalAmerican society for clinical oncologyEuropean hematology association

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

United statesIsabella zinckVivek subbiahDan connellyNovartis tafinlarNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationNovartis oncology communications